Hide and seek: Tell-tale signs of breast cancer lurking in the blood

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 289-302

  Guttery, David S ^a   Blighe, Kevin ^a   Page, Karen ^a   Marchese, Stephanie D ^b   Hills, Allison ^b   Coombes, R Charles ^b   Stebbing, Justin ^b   Shaw, Jacqueline A ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b Hammersmith Hospital Campus   (United Kingdom)

Author keywords

Breast cancer; Cell free DNA; Circulating miRNA; Circulating nucleic acids; Principal component analysis

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; ATM PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; CELL FREE DNA; DEATH ASSOCIATED PROTEIN KINASE; DEOXYRIBONUCLEASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE P1; HEMOGLOBIN BETA CHAIN; K RAS PROTEIN; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 125B; MICRORNA 141; MICRORNA 155; MICRORNA 21; MICRORNA 214; MICRORNA 375; NUCLEIC ACID; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BIOINFORMATICS; BLOOD; BLOOD CHEMISTRY; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CIRCULATING TUMOR CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE SEVERITY; DNA MICROARRAY; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA CLEAVAGE; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; DNA; FEMALE; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PRINCIPAL COMPONENT ANALYSIS;

EID: 84878109324     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9414-4     Document Type: Review

References (183)

1. Taplin, S., Abraham, L., Barlow, W. E., Fenton, J. J., Berns, E. A., Carney, P. A., et al. (2008). Mammography facility characteristics associated with interpretive accuracy of screening mammography. Journal of the National Cancer Institute, 100(12), 876-887.
2. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25(33), 5287-5312.
3. O'Hanlon, D. M., Kerin, M. J., Kent, P., Maher, D., Grimes, H., & Given, H. F. (1995). An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. British Journal of Cancer, 71(6), 1288-1291.
4. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353(16), 1659-1672.
5. Uehara, M., Kinoshita, T., Hojo, T., Akashi-Tanaka, S., Iwamoto, E., & Fukutomi, T. (2008). Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International Journal of Clinical Oncology, 13(5), 447-451.
6. Weigel, M. T., & Dowsett, M. (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-Related Cancer, 17(4), R245-R262.
7. Karrison, T. G., Ferguson, D. J., & Meier, P. (1999). Dormancy of mammary carcinoma after mastectomy. Journal of the National Cancer Institute, 91(1), 80-85.
8. Fisher, B., Jeong, J.H., Dignam, J., Anderson, S., Mamounas, E., Wickerham, D. L., et al. (2001). Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. Journal of National Cancer Institute Monographs, 2001(30), 62-66.
9. Wallgren, A., Bonetti, M., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M., Holmberg, S. B., et al. (2003). Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of Clinical Oncology, 21(7), 1205-1213.
10. Meltzer, A. (1990). Dormancy and breast cancer. Journal of Surgical Oncology, 43(3), 181-188.
11. Murray, C. (1995). Tumour dormancy: not so sleepy after all. Nature Medicine, 1(2), 117-118.
12. Kuukasjarvi, T., Karhu, R., Tanner, M., Kahkonen, M., Schaffer, A., Nupponen, N., et al. (1997). Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Research, 57(8), 1597-1604.
13. Gangnus, R., Langer, S., Breit, E., Pantel, K., & Speicher, M. R. (2004). Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clinical Cancer Research, 10(10), 3457-3464.
14. Stoecklein, N. H., & Klein, C. A. (2010). Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer, 126(3), 589-598.
15. Levenson, V. V. (2007). Biomarkers for early detection of breast cancer: what, when, and where? Biochimica et Biophysica Acta, 1770(6), 847-856.
16. Mandel, P., & Metais, P. (1948). Les acides nucléiques du plasma sanguin chez l'homme. Comptes Rendus de l'Académie des Sciences de Paris, 142, 241-243.
17. Leon, S. A., Shapiro, B., Sklaroff, D. M., & Yaros, M. J. (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Research, 37(3), 646-650.
18. Stroun, M., Anker, P., Lyautey, J., Lederrey, C., & Maurice, P. A. (1987). Isolation and characterization of DNA from the plasma of cancer patients. European Journal of Cancer & Clinical Oncology, 23(6), 707-712.
19. Cherepanova, A. V., Tamkovich, S. N., Bryzgunova, O. E., Vlassov, V. V., & Laktionov, P. P. (2008). Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Annals of the New York Academy of Sciences, 1137, 218-221.
20. Huang, Z. H., Li, L. H., & Hua, D. (2006). Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Letters, 243(1), 64-70.
21. Page, K., Powles, T., Slade, M. J., Tamburo de Bella, M., Walker, R. A., Coombes, R. C., et al. (2006). The importance of careful blood processing in isolation of cell-free DNA. Annals of the New York Academy of Sciences, 1075, 313-317.
22. Wang, B. G., Huang, H. Y., Chen, Y. C., Bristow, R. E., Kassauei, K., Cheng, C. C., et al. (2003). Increased plasma DNA integrity in cancer patients. Cancer Research, 63(14), 3966-3968.
23. Gong, B., Xue, J., Yu, J., Li, H., Hu, H., Yen, H., et al. (2012). Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer. Oncology Letters, 3(4), 897-900.
24. Zanetti-Dallenbach, R., Wight, E., Fan, A. X., Lapaire, O., Hahn, S., Holzgreve, W., et al. (2008). Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Research, 28(2A), 921-925.
25. Pathak, A. K., Bhutani, M., Kumar, S., Mohan, A., & Guleria, R. (2006). Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clinical Chemistry, 52(10), 1833-1842.
26. Anker, P., Stroun, M., & Maurice, P. A. (1975). Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Research, 35(9), 2375-2382.
27. Nawroz, H., Koch, W., Anker, P., Stroun, M., & Sidransky, D. (1996). Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Medicine, 2(9), 1035-1037.
28. Alix-Panabieres, C., Schwarzenbach, H., & Pantel, K. (2012). Circulating tumor cells and circulating tumor DNA. Annual Review of Medicine, 63, 199-215.
29. Jung, K., Fleischhacker, M., & Rabien, A. (2010). Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clinica Chimica Acta, 411(21-22), 1611-1624.
30. Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., et al. (2012). Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clinical Cancer Research, 18(12), 3462-3469.
31. Board, R. E., Wardley, A. M., Dixon, J. M., Armstrong, A. C., Howell, S., Renshaw, L., et al. (2010). Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment, 120(2), 461-467.
32. Silva, J. M., Gonzalez, R., Dominguez, G., Garcia, J. M., Espana, P., & Bonilla, F. (1999). TP53 gene mutations in plasma DNA of cancer patients. Genes, Chromosomes & Cancer, 24(2), 160-161.
33. Schwarzenbach, H., Muller, V., Stahmann, N., & Pantel, K. (2004). Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Annals of the New York Academy of Sciences, 1022, 25-32.
34. Shaw, J. A., Smith, B. M., Walsh, T., Johnson, S., Primrose, L., Slade, M. J., et al. (2000). Microsatellite alterations plasma DNA of primary breast cancer patients. Clinical Cancer Research, 6(3), 1119-1124.
35. Schwarzenbach, H., Eichelser, C., Kropidlowski, J., Janni, W., Rack, B., & Pantel, K. (2012). Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clinical Cancer Research
36. Yamamoto, N., Nakayama, T., Kajita, M., Miyake, T., Iwamoto, T., Kim, S. J., et al. (2012). Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Research and Treatment, 132(1), 165-173.
37. Hoque, M. O., Feng, Q., Toure, P., Dem, A., Critchlow, C. W., Hawes, S. E., et al. (2006). Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. Journal of Clinical Oncology, 24(26), 4262-4269.
38. Sharma, G., Mirza, S., Parshad, R., Gupta, S. D., & Ralhan, R. (2012). DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biology. doi: 10.1007/s13277-012-0443-y.
39. Page, K., Hava, N., Ward, B., Brown, J., Guttery, D. S., Ruangpratheep, C., et al. (2011). Detection of HER2 amplification in circulating free DNA in patients with breast cancer. British Journal of Cancer, 104(8), 1342-1348.
40. Diaz, L. A., Jr., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 486(7404), 537-540.
41. Shaw, J. A., Page, K., Blighe, K., Hava, N., Guttery, D., Ward, B., et al. (2012). Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Research, 22(2), 220-231.
42. Beck, J., Urnovitz, H. B., Mitchell, W. M., & Schutz, E. (2010). Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Molecular Cancer Research, 8(3), 335-342.
43. van de Wiel, M. A., Picard, F., van Wieringen, W. N., & Ylstra, B. (2011). Preprocessing and downstream analysis of microarray DNA copy number profiles. Briefings in Bioinformatics, 12(1), 10-21.
44. Ong, M., Mateo, J., Pope, L., Cassidy, A. M., Yap, T. A., Perkins, G., et al. (2012). Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials. Paper presented at the 2012 ASCO Annual Meeting
45. Lam, H. Y. K., Clark, M. J., Chen, R., Chen, R., Natsoulis, G., O'Huallachain, M., et al. (2012). Performance comparison of whole-genome sequencing platforms. Nature Biotechnology, 30(1), 78-82.
46. Archer, J., Baillie, G., Watson, J., Kellam, P., Rambaut, A., & Robertson, D. (2011). Characterizing Next Generation Sequencing Error and the Consequences for the Study of Intra-Patient Viral Diversity. Paper presented at the Eighteenth International Workshop on HIV Dynamics and Evolution, Galway, Republic of Ireland
47. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The sequence alignment/map format and SAMtools. Bioinformatics, 25(16), 2078-2079.
48. He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics, 5(7), 522-531.
49. Miranda, K. C., Huynh, T., Tay, Y., Ang, Y. S., Tam, W. L., Thomson, A. M., et al. (2006). A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell, 126(6), 1203-1217.
50. Bullrich, F., Fujii, H., Calin, G., Mabuchi, H., Negrini, M., Pekarsky, Y., et al. (2001). Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Research, 61(18), 6640-6648.
51. Cummins, J. M., He, Y., Leary, R. J., Pagliarini, R., Diaz, L. A., Jr., Sjoblom, T., et al. (2006). The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 103(10), 3687-3692.
52. Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Journal of the American Medical Association, 299(4), 425-436.
53. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834-838.
54. Rosenfeld, N., Aharonov, R., Meiri, E., Rosenwald, S., Spector, Y., Zepeniuk, M., et al. (2008). MicroRNAs accurately identify cancer tissue origin. Nature Biotechnology, 26(4), 462-469.
55. Rosenwald, S., Gilad, S., Benjamin, S., Lebanony, D., Dromi, N., Faerman, A., et al. (2010). Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Modern Pathology, 23(6), 814-823.
56. Mostert, B., Sieuwerts, A. M., Martens, J. W., & Sleijfer, S. (2011). Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Review of Molecular Diagnostics, 11(3), 259-275.
57. Ferracin, M., Veronese, A., & Negrini, M. (2010). Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 10(3), 297-308.
58. Lodes, M. J., Caraballo, M., Suciu, D., Munro, S., Kumar, A., & Anderson, B. (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One, 4(7), e6229.
59. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10513-10518.
60. Ji, X., Takahashi, R., Hiura, Y., Hirokawa, G., Fukushima, Y., & Iwai, N. (2009). Plasma miR-208 as a biomarker of myocardial injury. Clinical Chemistry, 55(11), 1944-1949.
61. Hunter, M. P., Ismail, N., Zhang, X., Aguda, B. D., Lee, E. J., Yu, L., et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS One, 3(11), e3694.
62. Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells. Journal of Biological Chemistry, 285(23), 17442-17452.
63. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., & Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654-659.
64. Brase, J. C., Wuttig, D., Kuner, R., & Sultmann, H. (2010). Serum microRNAs as non-invasive biomarkers for cancer. Molecular Cancer, 9, 306.
65. Turchinovich, A., Weiz, L., & Burwinkel, B. (2012). Extracellular miRNAs: the mystery of their origin and function. Trends in Biochemical Sciences.
66. Pigati, L., Yaddanapudi, S. C., Iyengar, R., Kim, D. J., Hearn, S. A., Danforth, D., et al. (2010). Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One, 5(10), e13515.
67. Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., et al. (2012). Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevention Research (Philadelphia, Pa.), 5(3), 492-497.
68. Wittmann, J., & Jack, H. M. (2010). Serum microRNAs as powerful cancer biomarkers. Biochimica et Biophysica Acta, 1806(2), 200-207.
69. Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251(3), 499-505.
70. Zhu, W., Qin, W., Atasoy, U., & Sauter, E. R. (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes, 2, 89.
71. Roth, C., Rack, B., Muller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12(6), R90.
72. van Schooneveld, E., Wouters, M. C., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., et al. (2012). Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research, 14(1), R34.
73. Wu, X., Somlo, G., Yu, Y., Palomares, M. R., Li, A. X., Zhou, W., et al. (2012). De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. Journal of Translational Medicine, 10, 42.
74. Schrauder, M. G., Strick, R., Schulz-Wendtland, R., Strissel, P. L., Kahmann, L., Loehberg, C. R., et al. (2012). Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 7(1), e29770.
75. Carlsson, J., Helenius, G., Karlsson, M., Lubovac, Z., Andrén, O., Olsson, B., et al. (2010). Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genetics and Cytogenetics, 202(2), 71-75.
76. Appaiah, H. N., Goswami, C. P., Mina, L. A., Badve, S., Sledge, G. W., Jr., Liu, Y., et al. (2011). Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Research, 13(5), R86.
77. Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer's Disease, 14(1), 27-41.
78. Mizuguchi, Y., Mishima, T., Yokomuro, S., Arima, Y., Kawahigashi, Y., Shigehara, K., et al. (2011). Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One, 6(1), e15304.
79. Ge, Q., Li, H., Yang, Q., Lu, J., Tu, J., Bai, Y., et al. (2011). Sequencing circulating miRNA in maternal plasma with modified library preparation. Clinica Chimica Acta, 412(21-22), 1989-1994.
80. Li, H., Guo, L., Wu, Q., Lu, J., Ge, Q., & Lu, Z. (2012). A comprehensive survey of maternal plasma miRNAs expression profiles using high-throughput sequencing. Clinica Chimica Acta, 413(5-6), 568-576.
81. Griffiths-Jones, S., Grocock, R. J., van Dongen, S., Bateman, A., & Enright, A. J. (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research, 34(suppl 1), D140-D144.
82. Griffiths-Jones, S., Saini, H. K., van Dongen, S., & Enright, A. J. (2008). miRBase: tools for microRNA genomics. Nucleic Acids Research, 36(suppl 1), D154-D158.
83. Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120(1), 15-20.
84. Team, R. D. C. (2008). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
85. Quackenbush, J. (2002). Microarray data normalization and transformation. Nature Genetics, 32(Suppl), 496-501.
86. Calza, S., Chen, S., & Pawitan, Y. (2010). LVSmiRNA: LVS normalization for Agilent miRNA data (R package version 1.4.0 ed.).
87. Calza, S., Valentini, D., & Pawitan, Y. (2008). Normalization of oligonucleotide arrays based on the least-variant set of genes. BMC Bioinformatics, 9(1), 140.
88. López-Romero, P. AgiMicroRna: Processing and differential expression analysis of agilent microRNA chips (R package version 2.4.0 ed.).
89. Gubian, S., Sewer, A., & PMP, S. A. (2010). ExiMiR: R functions for the normalization of Exiqon miRNA array data (R package version 1.2.0 ed.).
90. Huovilainen, O. P., & Lahti, L. pint - R/Bioconductor package for pairwise integration of functional genomics data.
91. Gentleman, R., & Falcon, S. microRNA: Data and functions for dealing with microRNAs (R package version 1.12.0 ed.).
92. Favero, F. RmiR.Hs.miRNA: Various databases of microRNA Targets (R package version 1.0.6 ed.).
93. Griffiths-Jones, S. (2004). The microRNA registry. Nucleic Acids Research, 32(suppl 1), D109-D111.
94. Kozomara, A., & Griffiths-Jones, S. (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Research, 39(suppl 1), D152-D157.
95. John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004). Human microRNA targets. PLoS Biology, 2(11), e363.
96. Papadopoulos, G. L., Reczko, M., Simossis, V. A., Sethupathy, P., & Hatzigeorgiou, A. G. (2009). The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Research, 37(suppl 1), D155-D158.
97. Wang, X., & El Naqa, I. M. (2008). Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics, 24(3), 325-332.
98. Krek, A., Grun, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., et al. (2005). Combinatorial microRNA target predictions. Nature Genetics, 37(5), 495-500.
99. Favero, F. RmiR: Package to work with miRNAs and miRNA targets with R (R package version 1.10.0 ed.).
100. Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews. Cancer, 2(8), 563-572.
101. Bernards, R., & Weinberg, R. A. (2002). A progression puzzle. Nature, 418(6900), 823.
102. Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58-68.
103. Stott, S. L., Hsu, C. H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., et al. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 107(43), 18392-18397.
104. Hayashi, N., & Yamauchi, H. (2012). Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer, 19(2), 110-117.
105. Yu, M., Stott, S., Toner, M., Maheswaran, S., & Haber, D. A. (2011). Circulating tumor cells: approaches to isolation and characterization. The Journal of Cell Biology, 192(3), 373-382.
106. Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., et al. (2012). Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One, 7(5), e33788.
107. Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clinical Cancer Research, 13(3), 920-928.
108. Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schutze, K., et al. (2000). Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. American Journal of Pathology, 156(1), 57-63.
109. Farace, F., Massard, C., Vimond, N., Drusch, F., Jacques, N., Billiot, F., et al. (2011). A direct comparison of cell search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer, 105(6), 847-853.
110. Gertler, R., Rosenberg, R., Fuehrer, K., Dahm, M., Nekarda, H., & Siewert, J. R. (2003). Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results in Cancer Research, 162, 149-155.
111. Sieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., et al. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute, 101(1), 61-66.
112. Tibbe, A. G., Miller, M. C., & Terstappen, L. W. (2007). Statistical considerations for enumeration of circulating tumor cells. Cytometry. Part A, 71(3), 154-162.
113. Goeminne, J. C., Guillaume, T., & Symann, M. (2000). Pitfalls in the detection of disseminated non-hematological tumor cells. Annals of Oncology, 11(7), 785-792.
114. Konigsberg, R., Obermayr, E., Bises, G., Pfeiler, G., Gneist, M., Wrba, F., et al. (2011). Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica, 50(5), 700-710.
115. Mikolajczyk, S. D., Millar, L. S., Tsinberg, P., Coutts, S. M., Zomorrodi, M., Pham, T., et al. (2011). Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. Journal of Oncology, 2011, 252361.
116. Park, J.M., Lee, J.Y., Lee, J.G., Jeong, H., Oh, J.M., Kim, Y.J., et al. (2012). Highly efficient assay of circulating tumor cells by selective sedimentation with a density gradient medium and microfiltration from whole blood. Analytical Chemistry
117. Barriere, G., Riouallon, A., Renaudie, J., Tartary, M., & Rigaud, M. (2012). Mesenchymal characterization: alternative to simple CTC detection in two clinical trials. Anticancer Research, 32(8), 3363-3369.
118. Friel, A. M., Corcoran, C., Crown, J., & O'Driscoll, L. (2010). Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Research and Treatment, 123(3), 613-625.
119. Stathopoulou, A., Ntoulia, M., Perraki, M., Apostolaki, S., Mavroudis, D., Malamos, N., et al. (2006). A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. International Journal of Cancer, 119(7), 1654-1659.
120. de Albuquerque, A., Kubisch, I., Ernst, D., Breier, G., Stamminger, G., Fersis, N., et al. (2012). Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clinical Laboratory, 58(5-6), 373-384.
121. Pachmann, K., Camara, O., Kavallaris, A., Krauspe, S., Malarski, N., Gajda, M., et al. (2008). Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of Clinical Oncology, 26(8), 1208-1215.
122. Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., et al. (2007). Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Journal of Clinical Oncology, 25(33), 5194-5202.
123. Pierga, J. Y., Bidard, F. C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., et al. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research, 14(21), 7004-7010.
124. Chen, X., Bonnefoi, H., Diebold-Berger, S., Lyautey, J., Lederrey, C., Faltin-Traub, E., et al. (1999). Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clinical Cancer Research, 5(9), 2297-2303.
125. Schwarzenbach, H., Alix-Panabieres, C., Muller, I., Letang, N., Vendrell, J. P., Rebillard, X., et al. (2009). Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clinical Cancer Research, 15(3), 1032-1038.
126. Paris, P. L., Kobayashi, Y., Zhao, Q., Zeng, W., Sridharan, S., Fan, T., et al. (2009). Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Letters, 277(2), 164-173.
127. Stathopoulou, A., Mavroudis, D., Perraki, M., Apostolaki, S., Vlachonikolis, I., Lianidou, E., et al. (2003). Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Research, 23(2C), 1883-1890.
128. Stathopoulou, A., Vlachonikolis, I., Mavroudis, D., Perraki, M., Kouroussis, C., Apostolaki, S., et al. (2002). Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology, 20(16), 3404-3412.
129. Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., et al. (2009). Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. Journal of Clinical Oncology, 27(13), 2177-2184.
130. Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Bolonaki, I., Stathopoulou, A., et al. (2006). Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. Journal of Clinical Oncology, 24(23), 3756-3762.
131. Sieuwerts, A. M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F. E., Stouthard, J. M., et al. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research, 17(11), 3600-3618.
132. Madhavan, D., Zucknick, M., Wallwiener, M., Cuk, K., Modugno, C., Scharpff, M., et al. (2012). Circulating microRNAs as surrogate markers for circulating tumour cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research
133. Payne, R. E., Hava, N. L., Page, K., Blighe, K., Ward, B., Slade, M., et al. (2012). The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. British Journal of Cancer, 106(2), 375-382.
134. Mazlum, N., Özer, A., & Mazlum, S. (1999). Interpretation of water quality data by principal components. Turkish Journal of Engineering and Environmental Sciences, 23, 19-26.
135. Joliffe, I. T. (2002). Principal components analysis (2nd ed.). NY: Springer.
136. Chakravarty, M. M., Aleong, R., Leonard, G., Perron, M., Pike, G. B., Richer, L., et al. (2011). Automated analysis of craniofacial morphology using magnetic resonance images. PLoS One, 6(5), e20241.
137. Bicciato, S., Luchini, A., & Di Bello, C. (2003). PCA disjoint models for multiclass cancer analysis using gene expression data. Bioinformatics, 19(5), 571-578.
138. Meng, Z., Zaykin, D. V., Xu, C.-F., Wagner, M., & Ehm, M. G. (2003). Selection of genetic markers for association analyses, using linkage disequilibrium and haplotypes. The American Journal of Human Genetics, 73(1), 115-130.
139. Lin, Z., & Altman, R. B. (2004). Finding haplotype tagging SNPs by use of principal components analysis. The American Journal of Human Genetics, 75(5), 850-861.
140. Parsons, K. J., Cooper, W. J., & Albertson, R. C. (2009). Limits of principal components analysis for producing a common trait space: implications for inferring selection, contingency, and chance in evolution. PLoS One, 4(11), e7957.
141. Chatfield, C., & Collins, A. J. (1980). Introduction to multivariate analysis. NY: Chapman and Hall.
142. Kaiser, H. (1960). The application of electronic computers to factor analysis. Educational and Psychological Measurement, 20(1), 141-151.
143. Cattell, R. B. (1966). The scree test for the number of factors. Multivariate Behavioral Research, 1, 629-637.
144. Mahloch, J. L. (1974). Multivariate techniques for water quality analysis. Journal of the Environmental Engineering Division, 100(5), 1119-1132.
145. Madsen, T. (2007). Multivariate data analysis with PCA, CA and MS. http://www.archaeoinfo.dk/PDF%20files/Multivariate%20data%20analysis.pdf. Accessed 15 Oct 2012.
146. Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996). Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology, 14(8), 2197-2205.
147. Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J., et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486(7403), 346-352.
148. Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nature Genetics, 33(1), 49-54.
149. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530-536.
150. Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005). Breast cancer metastasis: markers and models. Nature Reviews. Cancer, 5(8), 591-602.
151. Landemaine, T., Jackson, A., Bellahcene, A., Rucci, N., Sin, S., Abad, B. M., et al. (2008). A six-gene signature predicting breast cancer lung metastasis. Cancer Research, 68(15), 6092-6099.
152. Driouch, K., Landemaine, T., Sin, S., Wang, S., & Lidereau, R. (2007). Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clinical & Experimental Metastasis, 24(8), 575-585.
153. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine, 347(25), 1999-2009.
154. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews. Cancer, 3(6), 453-458.
155. Smid, M., Wang, Y., Klijn, J. G., Sieuwerts, A. M., Zhang, Y., Atkins, D., et al. (2006). Genes associated with breast cancer metastatic to bone. Journal of Clinical Oncology, 24(15), 2261-2267.
156. Bae, Y. K., Shim, Y. R., Choi, J. H., Kim, M. J., Gabrielson, E., Lee, S. J., et al. (2005). Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Research and Treatment, 37(4), 233-240.
157. Urquidi, V., & Goodison, S. (2007). Genomic signatures of breast cancer metastasis. Cytogenetic and Genome Research, 118(2-4), 116-129.
158. Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., et al. (1994). Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proceedings of the National Academy of Sciences of the United States of America, 91(6), 2156-2160.
159. Han, W., Han, M. R., Kang, J. J., Bae, J. Y., Lee, J. H., Bae, Y. J., et al. (2006). Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer, 6, 92.
160. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065-7070.
161. Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews. Cancer, 6(11), 857-866.
162. Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682-688.
163. Shi, M., Liu, D., Duan, H., Shen, B., & Guo, N. (2010). Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer and Metastasis Reviews, 29(4), 785-799.
164. Molloy, T. J., Roepman, P., Naume, B., & van't Veer, L. J. (2012). A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients. PLoS One, 7(2), e32426.
165. Alitalo, A., & Detmar, M. (2012). Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene, 31(42), 4499-4508.
166. Montel, V., Huang, T. Y., Mose, E., Pestonjamasp, K., & Tarin, D. (2005). Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. American Journal of Pathology, 166(5), 1565-1579.
167. Pandis, N., Teixeira, M. R., Adeyinka, A., Rizou, H., Bardi, G., Mertens, F., et al. (1998). Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes, Chromosomes & Cancer, 22(2), 122-129.
168. Smeets, A., Daemen, A., Vanden Bempt, I., Gevaert, O., Claes, B., Wildiers, H., et al. (2011). Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Research and Treatment, 129(3), 767-776.
169. Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V., & Pantel, K. (2012). Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat, 134(3), 933-941.
170. Schwarzenbach, H., Muller, V., Beeger, C., Gottberg, M., Stahmann, N., & Pantel, K. (2007). A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Research, 9(5), R66.
171. Barekati, Z., Radpour, R., Lu, Q., Bitzer, J., Zheng, H., Toniolo, P., et al. (2012). Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer, 12, 244.
172. Gobel, G., Auer, D., Gaugg, I., Schneitter, A., Lesche, R., Muller-Holzner, E., et al. (2011). Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Research and Treatment, 130(1), 109-117.
173. Matuschek, C., Bolke, E., Lammering, G., Gerber, P. A., Peiper, M., Budach, W., et al. (2010). Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. European Journal of Medical Research, 15(7), 277-286.
174. Van der Auwera, I., Elst, H. J., Van Laere, S. J., Maes, H., Huget, P., van Dam, P., et al. (2009). The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. British Journal of Cancer, 100(8), 1277-1286.
175. Dulaimi, E., Hillinck, J., Ibanez de Caceres, I., Al-Saleem, T., & Cairns, P. (2004). Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clinical Cancer Research, 10(18 Pt 1), 6189-6193.
176. Martinez-Galan, J., Torres, B., Del Moral, R., Munoz-Gamez, J. A., Martin-Oliva, D., Villalobos, M., et al. (2008). Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biology & Therapy, 7(6), 958-965.
177. Papadopoulou, E., Davilas, E., Sotiriou, V., Georgakopoulos, E., Georgakopoulou, S., Koliopanos, A., et al. (2006). Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Annals of the New York Academy of Sciences, 1075, 235-243.
178. Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S., Turchinovich, A., et al. (2012). Circulating microRNAs in plasma as early detection markers for breast cancer. International Journal of Cancer.
179. Cookson, V. J., Bentley, M. A., Hogan, B. V., Horgan, K., Hayward, B. E., Hazelwood, L. D., et al. (2012). Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncology (Dordrecht), 35(4), 301-308.
180. Wang, H., Tan, G., Dong, L., Cheng, L., Li, K., Wang, Z., et al. (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7(4), e34210.
181. Jung, E. J., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., et al. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118(10), 2603-2614.
182. Zhao, R., Wu, J., Jia, W., Gong, C., Yu, F., Ren, Z., et al. (2011). Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie, 34(12), 675-680.
183. Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C. B., & Liu, S. (2010). A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One, 5(10), e13735.